+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

A

Actively Recruiting

Transthyretin Amyloid Cardiomyopathy ATTR-CM is a serious heart condition caused by the buildup of misfolded transthyretin protein in the heart muscle, leading to heart stiffness and progressive heart failure. There are two types a hereditary form and a wild-type form related to aging. Diagnosing ATTR-CM can be challenging because its symptoms resemble other heart diseases, but advances in medical imaging have improved early detection. Acoramidis is a new medication designed to stabilize the transthyretin protein and prevent harmful buildup. The ACO-REAL study is an observational research project aiming to collect real-world data on acoramidis use in patients with ATTR-CM. This study will observe adults diagnosed with either wild-type or variant ATTR-CM who are starting acoramidis treatment as part of their routine care in approximately 20 European countries. It includes patients new to treatment as well as those who have received other therapies. Researchers will document patient characteristics, how acoramidis is used in everyday clinical practice, and any side effects. The study does not introduce experimental treatments but follows patients receiving acoramidis according to normal medical standards. Participants will be followed for about 12 to 15 months after starting acoramidis. Researchers will collect data on heart function, functional capacity like walking ability, overall health, quality of life, and healthcare usage such as hospital visits. They will also monitor for adverse events during this period. This information aims to improve understanding of ATTR-CM and optimize patient care in real-world settings.

Age: 18Years +All Genders
17 locations